What do the numbers say about Sanofi India (SANOFI)? Here's a look at its financials, valuation, and ownership data.
Sanofi India Revenue Trend
Top-line pressure showed for Sanofi India, with revenue declining 8.7% to ₹1,837 Cr in FY2025.
On a longer horizon, Sanofi India's top line has been slowly shrinking — a 1.8% annual decline from ₹2,193 Cr to ₹1,837 Cr over 10 years.
Sanofi India is a mid-sized pharmaceuticals company by revenue, with a top line of ₹1,837 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,837 Cr | -8.7% |
| FY2024 | ₹2,013 Cr | -29.4% |
| FY2023 | ₹2,851 Cr | +2.9% |
| FY2022 | ₹2,770 Cr | -8.6% |
| FY2021 | ₹3,031 Cr | — |
View Sanofi India's full 10-year revenue trend with CAGR analysis →
Sanofi India Profitability
The bottom line took a hit: Sanofi India's net profit slipped 21.0% to ₹327 Cr in FY2025.
Net profit margin compressed to 17.8% in FY2025 from 20.5% in FY2024.
On an EPS basis, the company earned ₹141.85 (diluted) in FY2025 versus ₹179.46 in FY2024.
Is Sanofi India Undervalued
Sanofi India shares are currently trading at ₹3,381.80.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Sanofi India Shareholding Pattern
At 60.4%, the promoter stake has been flat for the past 4 quarters.
FII ownership stands at 5.7%, up from the 5.6% recorded a year ago.
Domestic institutions moved their stake down to 19.9% from 22.3% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 60.4% | 5.7% | 19.9% | 14.0% |
| Mar 2026 | 60.4% | 5.6% | 21.1% | 12.8% |
| Dec 2025 | 60.4% | 5.5% | 21.3% | 12.7% |
| Sep 2025 | 60.4% | 5.6% | 22.3% | 11.8% |
Track quarterly shareholding changes for Sanofi India →
Sanofi India Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹12.55B at the end of FY2025, down 22.1% from ₹16.12B a year earlier.
Inventories is the largest block at 24.8%, followed by Cash & ST Investments at 21.0% and Property, Plant & Equipment at 20.8%.
Equity makes up 59.7% of liabilities and equity, with debt at 1.4% and operating liabilities at 38.9%. Over the year, debt is down 7.8% and equity is down 12.9%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 2.63B |
| Receivables | 1.77B |
| Inventories | 3.12B |
| Property, Plant & Equipment | 2.61B |
| Intangibles & Goodwill | 7.00M |
| Other Assets | 2.42B |
| Category | Value |
|---|---|
| Equity | 7.49B |
| Short-term Debt | 41.00M |
| Long-term Debt | 137.00M |
| Trade Payables | 1.94B |
| Other Liabilities | 2.94B |
Sanofi India Key Highlights
Here's the bottom line on Sanofi India (SANOFI) based on the latest available financials.
Revenue of ₹1,837 Cr in FY2025, down 8.7% year-over-year.
Long-term revenue has been contracting at 1.8% annually over 10 years.
The company is profitable, with a net margin of 17.8% and net income of ₹327 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Sanofi India.